Celyad « Terug naar discussie overzicht

celyad 2020

3.398 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 ... 166 167 168 169 170 » | Laatste
twopence
0
Fleurie is vermoedelijk een dame en die ga je niet naar de kleur van haar onderbroek vragen.
Speedbul
0
quote:

Twin schreef op 7 januari 2020 10:49:

Hello speedbull ,
Twin here, you're last post : going about celyad or general? Thank you for you're answer
kind regardes twin
Hi Twin,
1) On one side, it seem's that there are more companies looking now at NKG2D as a way to target cancers.
2) NKG2D is more universal since it may liaise to 80% of cancers
3) Celyad is also testing the shRNA platform which should provide better and longer persistance of NKG2D cells
4) It seem's that shRNA vector may also carry additional and complementary components to better address cancer specificities
5) Finally, with its allogeneic approach, Celyad is now closing the loop and should be able to position itself as a key player in imunotherapy IF, everything work as planned and IF Celyad brings all these technologies before competition.
Speedbul
0
A different approach was utilized by Celyad Inc. to develop two CAR T-cell products (allogeneic CYAD-101 and autologous CYAD-01) bearing natural killer receptors (NKRs) targeting a range of ligands expressed across various cancers. The important feature of CYAD-101 is the expression of the inhibitory peptide T-cell receptor (TCR) inhibitory molecule (TIM) that lowers the TCR-signaling and thus the probability of developing GvHD. These products are now being investigated in Phase I clinical trials. In the alloSHRINK trial (colorectal cancer, CYAD-101) two out of 12 patients achieved partial remission (PR) and another five achieved SD [135]. In THINK trial (AML, CYAD-01) anti-leukemic activity was achieved in six out of 13 patients [136]. No significant toxicity was reported for either of the CAR T-cell products.
Allogeneic CAR T-cell therapy may face significant obstacles on its way to successful clinical application. The major challenge is to achieve prolonged CAR T-cell persistence without continuing depletion of patient immune cells described by Qasim et al. [133]. The approach of disrupting human leukocyte antigen (HLA) expression in CAR T-cells is substantially limited by NK- and NKT-cells that are likely to eliminate HLA-negative cells. Additional modifications in HLA-H, HLA-E, or HLA-G expression are required to keep therapeutic cells protected from the host NKs.
www.mdpi.com/2072-6694/12/1/125/htm
twopence
0
quote:

nat1966 schreef op 7 januari 2020 12:55:

amai fleuri aan 10.34 gekocht ,nog een eind te gaan
Zij is daar eerder dan ik. (€11,44)
[verwijderd]
0
Thank you speedbull for you re answer, so everybody do rechurch NKG2D, but celyad still on top ? And whats mean IF ? i hope celyad change this year, thank you a lot speedbull
Have a nice day greetz twin
g62333
0
quote:

twopence schreef op 7 januari 2020 14:07:

[...]Zij is daar eerder dan ik. (€11,44)
11,21 voor mij maar mss koop ik nog wat bij om onder de 11 te geraken maar zit ook al aan 1600 ondertussen....
twopence
0
Dan moet je niet te lang wachten g62333. De kans om onder 11 te geraken kan zo vervlogen zijn.
stoppelbaard
0
net niet groen dus, -0,02 €...wat een gekke beursdag, het begon vanmorgen sterk en met verloop van tijd leek het wel of iedereen eieren voor z`n geld koos... hoop voor Celyad dat we nu echt hogere regionen gaan opzoeken... ik heb echt nog veel in te halen...
fleurie
0
Weet iemand de vinger er op te leggen , als je nu naar het order boek kijk en naar de lage omzet wat gebeurd hier!!!
[verwijderd]
0
Dag nat1966 enige wat ik vind is de tittel op boursorama site ,met post wie er komt van aandeelhouder

uitnodiging Celyad 8 januari

www.boursorama.com/bourse/forum/FF11-...
3.398 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 ... 166 167 168 169 170 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 apr 2024 17:35
Koers 0,335
Verschil +0,020 (+6,35%)
Hoog 0,339
Laag 0,315
Volume 17.101
Volume gemiddeld 20.924
Volume gisteren 1.939

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront